Overview
Group 3 brings together the topics 5, 6, 7, 8 and TR3 of the UMR 1260 INSERM-UNISTRA, which share the following focus:
- Innovative research for personalized medicine: our primary goal is to develop cutting-edge, tailored therapeutic solutions to address various cancerous and inflammatory diseases (e.g. lung cancer, urological cancers, colorectal cancer, chronic inflammatory bowel diseases).
- Strategy towards the complexity of living systems: we specialize in engineering advanced 3D cellular models that more accurately replicate patient heterogeneity and/or tissue organization (multicellularity, 3D structure, microenvironment).
By combining these models with patient-derived data, we investigate:- The molecular and cellular mechanisms involved in the onset, progression and treatment resistance of diseases to identify novel therapeutic targets,
- The impact of toxic molecules and new therapeutic approaches.
- Multidisciplinary expertise and state-of-the-art technologies: a synergy between researchers, university lecturers and researchers, engineers, technicians, pharmacists and physicians — strengthened by collaborations within international consortia (e.g. MITI2) — enables us to leverage a wide range of cutting-edge technologies, such as 3D bioprinting, vascularization/innervation, microfluidic chips, multi-omics approaches and video microscopy. We also have privileged access to patient tissues (sample collections, organoids/tumoroids) and are training the next generation of pioneers in biomedical research.
Organization of Group 3
Publications
Lê, H. et al. In vitro vascularized immunocompetent patient-derived model to test cancer therapies. iScience26, (2023). https://doi.org/10.1016/j.isci.2023.108094
Reita, D. et al. Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance. Cancers14, 1321 (2022). https://doi.org/10.3390/cancers14051321
Beck, M. et al. The atypical cadherin MUCDHL antagonizes colon cancer formation and inhibits oncogenic signaling through multiple mechanisms. Oncogene40, 522–535 (2021). https://doi.org/10.1038/s41388-020-01546-y
Lang, H. et al. Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapies. Front Oncol12, 930731 (2022). https://doi.org/10.3389/fonc.2022.930731
Audebrand, A. et al. Second-generation prokineticin PKR1 receptor agonists: Advancing cardioprotection against chemotherapy-induced toxicity. British Journal of Pharmacology183, 3377–3394 (2026). https://doi.org/10.1111/bph.70394
Hassan, S. et al. Quercetin potentializes the respective cytotoxic activity of gemcitabine or doxorubicin on 3D culture of AsPC-1 or HepG2 cells, through the inhibition of HIF-1α and MDR1. PLOS ONE15, e0240676 (2020). https://doi.org/10.1371/journal.pone.0240676